Menu About us Vaccines Vaccines We are one of the world’s largest vaccines companies, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential. The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta (US) site dedicated to smallpox vaccine production since 1882. Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. View video on YouTube Our Vaccines business has a portfolio of more than 20 vaccines to help protect people from a range of diseases throughout their lives. We supply these vaccines to people living in over 160 countries. The business generated sales of £7 billion in 2020. Our marketplace Vaccination is recognised worldwide as one of the best investments that any government or healthcare organisation can make. In 2012, the WHO and its 194 member states published an action plan on vaccination to extend access to immunization to everyone in the world, promote innovation in the vaccines industry and prevent millions of deaths. This plan involves more equitable access to existing vaccines for people in all communities, the introduction of new and improved vaccines and accelerated research and development for the next generation of vaccines and technologies. Our strategy Our strategy is to bring differentiated, high-quality, and needed vaccines to as many people as possible. To do this we focus on creating a strong patient and payer focused pipeline, maintaining valuable partnerships with our local operating countries, and ensuring sustainable access and affordability. Quality and manufacturing Our Vaccines business has 12 manufacturing sites located around the world. This global network gives us a strategic supply capability that enabled us to produce and deliver 582 million doses of vaccine in 2020 and achieve our best supply performance ever. The highest quality standards are ensured in each step of the vaccine production process, including vaccine components, facilities and equipment, people training, qualification, certification and storage. Each of our vaccines is produced to the same quality standard, regardless of where in the world the vaccine will be used. We are continuously investing in our manufacturing facilities, improving our processes and building partnerships to ensure we meet the global growing needs for high quality vaccines. Research and collaboration Innovation is the beating heart of our business. Without it, there will be no new vaccines for the many diseases that still threaten individuals, families and communities around the world. Our Vaccines scientists work in three global R&D centres, in Belgium, Italy and the US – and a fourth virtual R&D centre dedicated to mRNA technology. We are focused on discovering and developing novel vaccines across a range of pressing public health threats. Our efforts are concentrated on those possible vaccines which may offer significant improvements over existing options or target diseases for which no vaccines yet exist. Our approach is to make the most of our own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Our vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. We have much to offer and through collaboration we can achieve so much more. We have a long track record of collaborating with governments, healthcare providers, regulators, academic institutions, non-governmental organisations, vaccine producers and other key partners to tackle public health challenges around the world. Other business areas Pharmaceuticals Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. Consumer Healthcare Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend. RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL